| __timestamp | Neurocrine Biosciences, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 5758000 |
| Thursday, January 1, 2015 | 33800000 | 8423000 |
| Friday, January 1, 2016 | 35900000 | 11986000 |
| Sunday, January 1, 2017 | 1254000 | 15215000 |
| Monday, January 1, 2018 | 4889000 | 15356000 |
| Tuesday, January 1, 2019 | 7400000 | 16660000 |
| Wednesday, January 1, 2020 | 10100000 | 52459000 |
| Friday, January 1, 2021 | 14300000 | 75061000 |
| Saturday, January 1, 2022 | 23200000 | 87221000 |
| Sunday, January 1, 2023 | 39700000 | 83779000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing insights
In the competitive landscape of biopharmaceuticals, cost efficiency is a critical metric. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Neurocrine Biosciences started with a cost of revenue of approximately $14 million in 2014, peaking at nearly $40 million by 2023. In contrast, Supernus Pharmaceuticals began with a modest $5.8 million, surging to an impressive $83.8 million in the same period. This represents a staggering 1,345% increase for Supernus, compared to Neurocrine's 184% growth. The data highlights Supernus's aggressive expansion strategy, reflected in its higher cost of revenue. As the industry evolves, understanding these financial dynamics is crucial for stakeholders aiming to navigate the biopharmaceutical sector's complexities.
Analyzing Cost of Revenue: Merck & Co., Inc. and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses